Vitamin D, Bone Mineral Density and Fracture Risk Assessment in Patients with Neuroendocrine Tumors Abstract #1998

Introduction: Some papers have recently described an association between neuroendrocrine tumors (NET) and both vitamin D deficiency (VDD) and low bone mineral density (BMD). The ten-year risk of osteoporotic fractures can be calculated with the FRAX algorithm.
Aim(s): Aim of this study was evaluating BMD, VDD and FRAX scores in a cohort of NET patients.
Materials and methods: The study included 30 consecutive unselected patients (56.7% male, mean age 65.5±11.0 years) with a diagnosis of NET. All the patients underwent dual X-ray absorptiometry scan (DXA). FRAX was calculated in the whole sample and mineral metabolism serum indices were measured.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Franco Grimaldi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#57 Clinical and demographic characteristics in patients newly diagnosed with neuroendocrine tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are tumors that form from cells that release hormones in response to a signal from the nervous system. These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Chi-Chang Chen
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#162 Different sites of rare metastases in neuroendocrine tumor patients detected by Ga-68 somatostatin receptor PET/CT
Introduction: The most common sites of metastases in neuroendocrine tumors are liver, lymph nodes, and bone.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Baum R P, ...
#180 Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
Introduction: The role of anti-angiogenic agents in GEP-NETS remains to be established. CD105 (Endoglin) identifies the TGF-ß1 receptor which is expressed on endothelial cells involved in tumor angiogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Carlos A. S. Soares